Phathom Pharmaceuticals Inc (PHAT) - Total Assets
Based on the latest financial reports, Phathom Pharmaceuticals Inc (PHAT) holds total assets worth $240.29 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Phathom Pharmaceuticals Inc - Total Assets Trend (2018–2024)
This chart illustrates how Phathom Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Phathom Pharmaceuticals Inc (PHAT) total market value for the company's overall valuation and market capitalisation.
Phathom Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Phathom Pharmaceuticals Inc's total assets of $240.29 Million consist of 95.2% current assets and 4.8% non-current assets. Review PHAT liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 78.6% |
| Accounts Receivable | $38.80 Million | 10.3% |
| Inventory | $3.21 Million | 0.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Phathom Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Phathom Pharmaceuticals Inc (PHAT) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Phathom Pharmaceuticals Inc's current assets represent 95.2% of total assets in 2024, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 78.6% of total assets in 2024, down from 97.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 10.3% of total assets.
Phathom Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Phathom Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Phathom Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.23 | 5.73 | 5.25 |
| Quick Ratio | 2.19 | 5.68 | 5.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $114.66 Million | $308.53 Million | $235.84 Million |
Phathom Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Phathom Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 25.37 |
| Latest Market Cap to Assets Ratio | 1.60 |
| Asset Growth Rate (YoY) | -8.6% |
| Total Assets | $378.32 Million |
| Market Capitalization | $604.60 Million USD |
Valuation Analysis
Above Book Valuation: The market values Phathom Pharmaceuticals Inc's assets above their book value (1.60x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Phathom Pharmaceuticals Inc's assets decreased by 8.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Phathom Pharmaceuticals Inc (2018–2024)
The table below shows the annual total assets of Phathom Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $378.32 Million | -8.58% |
| 2023-12-31 | $413.84 Million | +151.10% |
| 2022-12-31 | $164.81 Million | -13.00% |
| 2021-12-31 | $189.43 Million | -35.81% |
| 2020-12-31 | $295.11 Million | +14.75% |
| 2019-12-31 | $257.18 Million | +28411.97% |
| 2018-12-31 | $902.00K | -- |
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical t… Read more